Valo SPAC Presentation Deck
Clinical development: Development of OPL-0301, a biased S1P, agonist,
is designed to validate Opal's clinical acceleration capabilities
Valo's goal is to computationally define clinical hypotheses a priori and continuously refine them
throughout development, potentially enabling smaller, more precise trials and a faster path to approval
DATA INPUTS
Longitudinal clinical
data
Deep cardiovascular
disease data
Biological
knowledge graphs
Chemical and
molecular data
Valo
CLINICAL DEVELOPMENT
Phase III Phase II
BIOLOGICAL DISCOVERY
Target
Discovery
RWE
Diagnosis
Opal
PLATFORM
Phase I
Preclinical
Target ID
Lead Opt
Hit to
Lead
THERAPEUTIC DESIGN
PLATFORM OUTPUTS
Identify and characterize
patient subgroups
Identify and characterize
biomarkers
Select patient groups and
biomarker hypotheses
CLINICAL
DEVELOPMENT
Designed to
produce precisely
defined patient
selection criteria
2Q21
22View entire presentation